These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19555718)

  • 1. Cellular models for the screening and development of anti-hepatitis C virus agents.
    Gondeau C; Pichard-Garcia L; Maurel P
    Pharmacol Ther; 2009 Oct; 124(1):1-22. PubMed ID: 19555718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of human hepatocytes to investigate HCV infection.
    Pichard-Garcia L; Briolotti P; Larrey D; Sa-Cunha A; Suc B; Laporte S; Maurel P
    Methods Mol Biol; 2010; 640():447-62. PubMed ID: 20645067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system.
    Hao W; Duggal R
    Methods Mol Biol; 2009; 510():243-50. PubMed ID: 19009266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
    Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T
    Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.
    Aly HH; Shimotohno K; Hijikata M
    Biochem Biophys Res Commun; 2009 Feb; 379(2):330-4. PubMed ID: 19103167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
    Bourne N; Pyles RB; Yi M; Veselenak RL; Davis MM; Lemon SM
    Antiviral Res; 2005 Aug; 67(2):76-82. PubMed ID: 15927278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication.
    Yu L; Aoki C; Shimizu Y; Shimizu K; Hou W; Yagyu F; Wen X; Oshima M; Iwamoto A; Gao B; Liu W; Gao GF; Kitamura Y
    J Virol Methods; 2010 Nov; 169(2):380-4. PubMed ID: 20713089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hepatitis C virus RNA replicons by peptide aptamers.
    Trahtenherts A; Gal-Tanamy M; Zemel R; Bachmatov L; Loewenstein S; Tur-Kaspa R; Benhar I
    Antiviral Res; 2008 Mar; 77(3):195-205. PubMed ID: 18243349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-free cell culture system supplemented with lipid-rich albumin for hepatitis C virus (strain O of genotype 1b) replication.
    Abe K; Ikeda M; Ariumi Y; Dansako H; Kato N
    Virus Res; 2007 May; 125(2):162-8. PubMed ID: 17267063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cultures of human hepatocytes isolated from hepatitis C virus-infected cirrhotic livers as a model to study hepatitis C infection.
    Raymond VA; Selliah S; Ethier C; Houle R; Jouan L; Maniere T; Lamarre D; Willems B; Bilodeau M
    Liver Int; 2009 Jul; 29(6):942-9. PubMed ID: 19302183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.
    Ishii K; Murakami K; Hmwe SS; Zhang B; Li J; Shirakura M; Morikawa K; Suzuki R; Miyamura T; Wakita T; Suzuki T
    Biochem Biophys Res Commun; 2008 Jul; 371(3):446-50. PubMed ID: 18445476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture.
    Bartenschlager R
    Curr Opin Microbiol; 2006 Aug; 9(4):416-22. PubMed ID: 16814596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes.
    Podevin P; Carpentier A; Pène V; Aoudjehane L; Carrière M; Zaïdi S; Hernandez C; Calle V; Méritet JF; Scatton O; Dreux M; Cosset FL; Wakita T; Bartenschlager R; Demignot S; Conti F; Rosenberg AR; Calmus Y
    Gastroenterology; 2010 Oct; 139(4):1355-64. PubMed ID: 20600021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
    Helmy A
    Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview: in vitro models of HCV replication in different cell cultures.
    Tariq H; Manzoor S; Parvaiz F; Javed F; Fatima K; Qadri I
    Infect Genet Evol; 2012 Jan; 12(1):13-20. PubMed ID: 22061839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication.
    Sagan SM; Rouleau Y; Leggiadro C; Supekova L; Schultz PG; Su AI; Pezacki JP
    Biochem Cell Biol; 2006 Feb; 84(1):67-79. PubMed ID: 16462891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.